Mesoblast (MESO) Non-Current Assets (2014 - 2026)
Mesoblast (MESO) posted Non-Current Assets of $579.8 million for Q4 2025, little changed sequentially from $580.3 million in Q2 2025, and down 0.65% YoY from $583.6 million in Q4 2024.
Analysis
Mesoblast (MESO) Non-Current Assets (2014 - 2026) Analysis & Trends
Mesoblast has reported Non-Current Assets for 11 years, with the latest figure at $579.8 million in Q4 2025.
- Quarterly Non-Current Assets fell 0.65% year-over-year to $579.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $579.8 million (down 0.65% YoY) and the FY2025 annual result came in at $580.3 million, changed 0.4% from the prior year.
- Non-Current Assets steadied at $579.8 million in Q4 2025 per MESO's latest filing, from $580.3 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $596.5 million in Q2 2021 and troughed at $579.8 million in Q4 2025.
- A 5-year average of $589.3 million and a median of $589.9 million in 2022 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2021 and 2022: Non-Current Assets fell 0.01% in 2021, then decreased 0.96% in 2022.
- Over 5 years, Non-Current Assets stood at $595.6 million in 2021, then fell by 0.96% to $589.9 million in 2022, then fell by 0.81% to $585.1 million in 2023, then dropped by 0.25% to $583.6 million in 2024, then declined by 0.65% to $579.8 million in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $579.8 million, $580.3 million, and $583.6 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.15 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 294.93 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.96 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 18.06 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - | 575.59 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 575.59 Mn |
| Dec 31, 2025 | 579.82 Mn |
| Jun 30, 2025 | 580.33 Mn |
| Dec 31, 2024 | 583.64 Mn |
| Jun 30, 2024 | 582.69 Mn |
| Dec 31, 2023 | 585.13 Mn |
| Jun 30, 2023 | 587.76 Mn |
| Mar 31, 2023 | 589.08 Mn |
| Dec 31, 2022 | 589.93 Mn |
| Sep 30, 2022 | 591.54 Mn |
| Jun 30, 2022 | 592.31 Mn |
| Mar 31, 2022 | 593.56 Mn |
| Dec 31, 2021 | 595.64 Mn |
| Sep 30, 2021 | 595.60 Mn |
| Jun 30, 2021 | 596.49 Mn |
| Mar 31, 2021 | 596.36 Mn |
| Dec 31, 2020 | 596.85 Mn |
| Sep 30, 2020 | 596.84 Mn |
| Jun 30, 2020 | 597.05 Mn |
| Mar 31, 2020 | 596.40 Mn |